Wire · opportunities
Medicover Genetics Launches Blood-Based MRD Test for Lung Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 October 2026 · Fusion42 review
Medicover Genetics launched OncoSentia MRD, a blood-based plasma assay for monitoring minimal residual disease in unresectable non-small cell lung cancer patients, offering a tumour-agnostic ctDNA detection method validated by the DART study and available across European markets.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now develop cancer monitoring tools that operate without tumour tissue samples using plasma-based ctDNA signals. Medicover Genetics showing clinical validation at scale means this approach is ready to be integrated into oncology care pathways across Europe.
◆ Coverage
1 source · 27 Oct 2026
◆ Related on Wire
◆ Topics